Indolent CD4+CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

被引：3

作者：

Ozdemirli, Metin ^{[1
]}

Loughney, Thomas M. ^{[2
]}

Deniz, Emre ^{[3
]}

Chahine, Joeffrey J. ^{[1
]}

Albitar, Maher ^{[4
]}

Pittaluga, Stefania ^{[5
]}

Sadigh, Sam ^{[6
]}

Armand, Philippe ^{[8
]}

Uren, Aykut ^{[3
]}

Anderson, Kenneth C. ^{[7
]}

机构：

[1] MedStar Georgetown Univ Hosp, Dept Pathol, 3800 Reservoir Rd NW, Washington, DC 20007 USA

[2] MedStar Georgetown Univ Hosp, Dept Gastroenterol, Washington, DC 20007 USA

[3] Georgetown Univ Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC USA

[4] Genom Testing Cooperat, Irvine, CA USA

[5] NIH, Bethesda, MD USA

[6] Brigham & Womens Hosp, Boston, MA USA

[7] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA

[8] Harvard Med Sch, Boston, MA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 390卷 / 22期

关键词：

D O I：

10.1056/NEJMoa2401530

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the SSU72 gene. In addition, numerous genetic alterations that may have contributed to malignant transformation were identified in the tumor sample. (Funded by MedStar Georgetown University Hospital.) A patient in whom diarrhea had developed 4 months after BCMA-directed CAR T-cell therapy for myeloma was found to have an indolent CD4+ lymphoma of the small intestine containing the CAR gene product.

引用

页码：2074 / 2082

页数：9

共 50 条

[1] CAR T-cell Therapy in Indolent Lymphoma
Jacobson, Caron A.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S178 - S179
[2] CD4+CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy
Ledergor, Guy
Fan, Zenghua
Wu, Kai
Mccarthy, Elizabeth
Hyrenius-Wittsten, Axel
Starzinski, Alec
Chang, Hewitt
Bridge, Mark
Kwek, Serena
Cheung, Alexander
Bylsma, Sophia
Hansen, Erik
Wolf, Jeffrey
Wong, Sandy
Shah, Nina
Roybal, Kole T.
Martin, Thomas
Ye, Chun J.
Fong, Lawrence
[J]. BLOOD ADVANCES, 2024, 8 (13) : 3562 - 3575
[3] Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
Hamilton, Mark P.
Sugio, Takeshi
Noordenbos, Troy
Shi, Shuyu
Bulterys, Philip L.
Liu, Chih Long
Kang, Xiaoman
Olsen, Mari N.
Good, Zinaida
Dahiya, Saurabh
Frank, Matthew J.
Sahaf, Bita
Mackall, Crystal L.
Gratzinger, Dita
Diehn, Maximilian
Alizadeh, Ash A.
Miklos, David B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (22): : 2047 - 2060
[4] T-Cell Cancer after CAR T-Cell Therapy
Mitchell, Emily
Vassiliou, George S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (22): : 2120 - 2121
[5] CAR T-Cell Therapy in Hodgkin Lymphoma
Ramos, Carlos A.
Quach, David H.
Rooney, Cliona M.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S9 - S9
[6] CAR T-cell therapy for indolent lymphoma: a new treatment paradigm? Comment
Holtzman, Noa G.
Shah, Nirali N.
[J]. LANCET ONCOLOGY, 2022, 23 (01): : 6 - 8
[7] CAR T-cell therapy
Cookson, Emma
[J]. LANCET HAEMATOLOGY, 2022, 9 (05): : E322 - E322
[8] CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
Mohty, Razan
Kharfan-Dabaja, Mohamed A.
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[9] CAR T-Cell therapy for the management of mantle cell lymphoma
Zoufang Huang
Vivek P. Chavda
Rajashri Bezbaruah
Hemant Dhamne
Dong-Hua Yang
Hong-Bing Zhao
[J]. Molecular Cancer, 22
[10] CAR T-cell therapy for B-cell lymphoma
Denlinger, Nathan
Bond, David
Jaglowski, Samantha
[J]. CURRENT PROBLEMS IN CANCER, 2022, 46 (01)

← 1 2 3 4 5 →